 CAMBRIDGE, Mass.--BUSINESS WIRE--Seres Therapeutics, Inc. Nasdaq: MCRB, a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection rCDI, will be presented at the IDWeek 2021 Virtual Conference Sept. 29-Oct. 3. The Company will be presenting seven posters and oral presentations related to SER-109 and C. difficile, including a late-breaker, as well as 